Jeevan Scientific Technology Ltd
₹ 39.2
-1.76%
12 Jun
3:05 p.m.
About
Incorporated in 1999, Jeevan Scientific Technology Ltd is an Independent Clinical Contract Research Organization which offers technology-driven clinical research solutions[1]
Key Points
- Market Cap ₹ 62.0 Cr.
- Current Price ₹ 39.2
- High / Low ₹ 67.8 / 38.0
- Stock P/E 83.8
- Book Value ₹ 32.2
- Dividend Yield 0.00 %
- ROCE 3.06 %
- ROE 1.48 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 38.0%
- Company has a low return on equity of -2.24% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.37 | 13.45 | 17.34 | 17.46 | 19.25 | 25.43 | 20.57 | 40.42 | 56.55 | 36.18 | 38.50 | 43.61 | |
| 5.31 | 11.10 | 15.15 | 14.24 | 15.93 | 19.62 | 26.35 | 23.79 | 39.46 | 34.83 | 34.12 | 37.14 | |
| Operating Profit | 1.06 | 2.35 | 2.19 | 3.22 | 3.32 | 5.81 | -5.78 | 16.63 | 17.09 | 1.35 | 4.38 | 6.47 |
| OPM % | 16.64% | 17.47% | 12.63% | 18.44% | 17.25% | 22.85% | -28.10% | 41.14% | 30.22% | 3.73% | 11.38% | 14.84% |
| 0.10 | 0.10 | 0.40 | 0.57 | 0.90 | 0.97 | 2.49 | 2.38 | 5.90 | 1.06 | 0.69 | 0.63 | |
| Interest | 0.66 | 0.74 | 1.28 | 1.48 | 1.67 | 2.09 | 2.57 | 1.88 | 0.96 | 1.01 | 0.75 | 1.04 |
| Depreciation | 0.27 | 0.28 | 0.67 | 1.18 | 2.06 | 3.07 | 3.91 | 3.96 | 3.68 | 5.02 | 5.55 | 5.29 |
| Profit before tax | 0.23 | 1.43 | 0.64 | 1.13 | 0.49 | 1.62 | -9.77 | 13.17 | 18.35 | -3.62 | -1.23 | 0.77 |
| Tax % | 0.00% | 0.00% | 34.38% | 8.85% | 46.94% | 16.05% | -20.06% | 14.58% | 33.19% | -16.85% | -14.63% | 3.90% |
| 0.23 | 1.44 | 0.42 | 1.03 | 0.25 | 1.36 | -7.81 | 11.26 | 12.26 | -3.00 | -1.05 | 0.74 | |
| EPS in Rs | 0.38 | 2.38 | 0.70 | 1.11 | 0.22 | 0.89 | -5.10 | 7.36 | 8.01 | -1.94 | -0.68 | 0.47 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.79% | 14.98% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 16% |
| 3 Years: | -8% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 16% |
| 3 Years: | -57% |
| TTM: | 170% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 16% |
| 3 Years: | -16% |
| 1 Year: | -28% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 8% |
| 3 Years: | -2% |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.04 | 6.04 | 6.04 | 9.28 | 11.46 | 15.30 | 15.30 | 15.30 | 15.30 | 15.48 | 15.48 | 15.83 |
| Reserves | -3.70 | -2.26 | -1.85 | 8.15 | 11.24 | 17.47 | 9.63 | 20.95 | 35.28 | 32.84 | 33.32 | 35.08 |
| 4.34 | 6.42 | 11.08 | 8.45 | 18.78 | 18.15 | 17.95 | 10.34 | 12.55 | 8.84 | 5.80 | 12.87 | |
| 1.20 | 6.75 | 5.30 | 5.10 | 7.82 | 9.90 | 10.00 | 17.18 | 14.75 | 6.59 | 5.32 | 6.84 | |
| Total Liabilities | 7.88 | 16.95 | 20.57 | 30.98 | 49.30 | 60.82 | 52.88 | 63.77 | 77.88 | 63.75 | 59.92 | 70.62 |
| 1.44 | 1.16 | 8.60 | 13.83 | 23.79 | 26.61 | 23.69 | 20.53 | 19.07 | 24.03 | 20.20 | 28.72 | |
| CWIP | 0.00 | 4.59 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.53 | 0.53 | 1.03 | 1.03 | 1.03 | 1.03 | 0.00 | 2.00 | 2.00 | 2.00 |
| 6.44 | 11.20 | 11.44 | 16.62 | 24.48 | 33.18 | 28.16 | 42.21 | 58.81 | 37.72 | 37.72 | 39.90 | |
| Total Assets | 7.88 | 16.95 | 20.57 | 30.98 | 49.30 | 60.82 | 52.88 | 63.77 | 77.88 | 63.75 | 59.92 | 70.62 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.27 | 2.39 | 3.95 | -8.13 | 3.73 | 2.41 | -1.19 | 4.73 | 19.56 | -6.29 | 2.74 | 2.96 | |
| -0.02 | -4.59 | -4.07 | -6.41 | -12.43 | -6.20 | -1.02 | -0.80 | -1.20 | -7.27 | -4.69 | -9.84 | |
| -0.22 | 2.21 | 0.23 | 14.57 | 9.88 | 6.07 | 0.44 | -0.13 | 5.67 | -10.03 | -3.66 | 6.58 | |
| Net Cash Flow | 0.03 | 0.01 | 0.11 | 0.03 | 1.18 | 2.28 | -1.77 | 3.80 | 24.03 | -23.59 | -5.61 | -0.30 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 143.82 | 199.19 | 152.19 | 232.25 | 305.65 | 208.26 | 106.47 | 112.52 | 49.12 | 117.83 | 113.10 | 120.44 |
| Inventory Days | 72.11 | 105.50 | 100.18 | 93.00 | ||||||||
| Days Payable | 98.78 | 318.92 | 184.48 | 273.00 | ||||||||
| Cash Conversion Cycle | 143.82 | 199.19 | 152.19 | 232.25 | 305.65 | 208.26 | 106.47 | 112.52 | 22.45 | -95.59 | 28.80 | -59.56 |
| Working Capital Days | 230.92 | 92.27 | 103.99 | 149.26 | 181.46 | 117.27 | 42.23 | 76.03 | 65.90 | 156.77 | 178.52 | 196.10 |
| ROCE % | 13.26% | 25.71% | 15.08% | 12.69% | 6.41% | 8.03% | -15.29% | 33.64% | 27.85% | -4.34% | -0.86% | 3.06% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Copy of Newspaper Cuttings of the Standalone and Consolidated Audited Financial Results for the quarter and year Ended 31st March, 2025.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report for FY ended March 31, 2025; no deviations reported.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - FY25 audited results approved; COO resigned; new internal and secretarial auditors appointed.
- Audited Results (Standalone And Consolidated) Of The Company For The Quarter And Year Ended 30.05.2025 30 May
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 30.05.2025
30 May - Audited FY25 results approved; new internal and secretarial auditors appointed; COO resigned effective May 30, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Services Offered:[1][2]
a) Clinical Trial Services:
Patient PK trials, Pharmacodynamic endpoint studies, Early & late phase clinical trials, Post-marketing surveillance studies, Investigator initiated and real-world evidence studies,
Clinical Trials Support for Complex Generics
& Biosimilars
b) Bioavailability & Bioequivalence Services:
MD/MV and subject sample analysis, Statistical Analysis and Data Management, SAS and Win Nonlin, CDISC, Healthy and Patient based BA/BE studies Food effect, Age Effect, Gender effect studies, Studies in both male and female subjects (Pre and Postmenopausal women), PK/PD endpoint studies, SAD and MAD studies, etc.
c) Pharmacovigilance Services:
Data migration, Database management, Literature search services, regulatory inspection /audit support, etc.